The promising in vitro results of for MG63-R1 and MG63-R2 cells and the in vivo tumor results observed with the combinations of NSM00158+CDDP and RCM1+CDDP suggest that targeting the CtBP1-FOXM1 complex prior to supplying chemotherapeutic drugs may significantly reduce osteosarcoma chemoresistance. Here, TNNI3 is linked to neoplasm.